Can Fite Valuation
| CANF Stock | USD 1.51 0.12 7.36% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Can Fite Biopharma shows a prevailing Real Value of $4.63 per share. The current price of the firm is $1.51. Our model approximates the value of Can Fite Biopharma from analyzing the firm fundamentals such as Operating Margin of (12.96) %, return on equity of -1.58, and Shares Outstanding of 6.1 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Can Fite's price fluctuation is risky at this time. Calculation of the real value of Can Fite Biopharma is based on 3 months time horizon. Increasing Can Fite's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Can stock is determined by what a typical buyer is willing to pay for full or partial control of Can Fite Biopharma. Since Can Fite is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Can Stock. However, Can Fite's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.51 | Real 4.63 | Hype 1.51 | Naive 1.6 |
The real value of Can Stock, also known as its intrinsic value, is the underlying worth of Can Fite Biopharma Company, which is reflected in its stock price. It is based on Can Fite's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Can Fite's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Can Fite Biopharma helps investors to forecast how Can stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Can Fite more accurately as focusing exclusively on Can Fite's fundamentals will not take into account other important factors: Can Fite Total Value Analysis
Can Fite Biopharma is currently estimated to have valuation of 5.8 M with market capitalization of 9.71 M, debt of 40 K, and cash on hands of 12.77 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Can Fite fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.8 M | 9.71 M | 40 K | 12.77 M |
Can Fite Investor Information
The book value of the company was currently reported as 0.0. The company recorded a loss per share of 2.6. Can Fite Biopharma last dividend was issued on the 10th of May 2019. The entity had 1:10 split on the 9th of January 2023. Based on the measurements of operating efficiency obtained from Can Fite's historical financial statements, Can Fite Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Can Fite Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Can Fite has an asset utilization ratio of 7.44 percent. This implies that the Company is making $0.0744 for each dollar of assets. An increasing asset utilization means that Can Fite Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Can Fite Ownership Allocation
Almost 98.49 percent of Can Fite outstanding shares are held by general public with 1.51 % by other corporate entities.Can Fite Profitability Analysis
The company reported the previous year's revenue of 743 K. Net Loss for the year was (7.63 M) with profit before overhead, payroll, taxes, and interest of 667 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Can Fite's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Can Fite and how it compares across the competition.
About Can Fite Valuation
The stock valuation mechanism determines Can Fite's current worth on a weekly basis. Our valuation model uses a comparative analysis of Can Fite. We calculate exposure to Can Fite's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Can Fite's related companies.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Can-Fite Biopharma operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 8 people.
Can Fite Growth Indicators
Investing in growth stocks can be very risky. If the company such as Can Fite does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4.3 M | |
| Forward Price Earnings | 2.9665 |
Complementary Tools for Can Stock analysis
When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |